At present, four types of chimeric antigen receptor T-cell (CAR-T) therapy are FDA approved for specific types of lymphoma: for relapsed or refractory (R/R) mantle cell lymphoma, brexucabtagene autoleucel, for R/R follicular lymphoma, axicabtagene ciloleucel, and for some aggressive forms of non-Hodgkin lymphoma, axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel. Despite these approvals, progression of disease and toxicity remain unresolved concerns associated with CAR-T therapy which are currently being investigated.
In this podcast, Caron Jacobson of the Dana-Farber Cancer Institute, Boston, MA, Stephen Schuster of the Perelman School of Medicine, Philadelphia, PA, Jeremy Abramson of the Massachusetts General Hospital Cancer Center, Boston, MA, Frederick Locke of the H. Lee Moffitt Cancer & Research Institute, Tampa, FL, David Miklos of Stanford University, Stanford, CA, Mazyar Shadman of the Fred Hutchinson Cancer Research Center, Seattle, WA, and Sonali Smith of the University of Chicago, Chicago, IL, discuss the latest updates on CAR-T therapy for the treatment of lymphoma.
iwNHL Session II: Understanding and harnessing the immune microenvironment against lymphoma
iwAL 2022 Session II: Novel treatment strategies in ALL
The role of the innate immune system in MDS
iwAL 2022 Session I: The standard of care in AML in 2022
iwNHL 2022 Session I: Advances in the treatment of T-cell lymphoma
ISA 2022: meeting highlights and recent updates in amyloidosis
Highlights from IMS 2022: managing high-risk & frail patients with myeloma and the prognostic value of MRD
Highlights from the 2022 Texas MPN Workshop: early intervention, disease progression & future targets
iwMDS 2022: Key highlights
Identifying high-risk myeloma and improving treatment strategies in these patients
Improving the efficiency of drug approvals in MDS
Highlights from the 2022 Texas MPN Workshop: advances in MPN treatment
The need for more effective first-line therapies in MDS
Myeloma 2022: day two highlights
The promise of CAR-T therapy in CLL and challenges in the field
Clonal hematopoiesis and pre-MDS states
T-cell engagers in multiple myeloma: current challenges and future outlooks
High-risk MDS: unmet needs and future treatment approaches
The importance of patient-reported outcomes in CAR-T recipients
CAR-T therapy in myeloma and lymphoma
Create your
podcast in
minutes
It is Free
Good Mood Revolution
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive